key: cord-0822537-h5ybl8k0 authors: Liu, Qiang title: The emerging roles of exosomal long non‐coding RNAs in bladder cancer date: 2022-01-03 journal: J Cell Mol Med DOI: 10.1111/jcmm.17152 sha: e715e522222c0d585179f402cd2dc81d3e6beb49 doc_id: 822537 cord_uid: h5ybl8k0 Extracellular vesicles (EVs), especially exosomes, have been reported to play essential roles as extracellular messengers by transporting goods in various diseases, while their potential roles in bladder cancer (BC) still remain to be further studied. BC exhibits a high degree of chemoresistance and metastatic ability, which may be affected by cancer‐derived exosomes that carry proteins, lipids and RNA. To date, the most studied exosomal molecular cargo is long non‐coding RNA (lncRNA). Although there is increasing interest in its role and function, there is relatively little knowledge about it compared with other RNA transcripts. Nevertheless, in the past ten years, we have witnessed increasing interest in the role and function of lncRNA. For example, lncRNAs have been studied as potential biomarkers for the diagnosis of BC. They may play a role as a therapeutic target in precision medicine, but they may also be directly involved in the characteristics of tumour progression, such as metastasis, epithelial‐mesenchymal transition and drug resistance. Cancer cells are on chemotherapy acting. The function of lncRNA in various cancer exosomes has not yet been determined. In this review, we summarize the current studies about the prominent roles of exosomal lncRNAs in genome integrity, BC progression and carcinogenic features. Bladder cancer (BC) is one of the most common malignant tumours of the genitourinary system, accounting for the 9th most common malignant tumour in the world. 1, 2 According to pathological classification, 90% of patients with BC have urothelial cancer. About one-third of these patients are first diagnosed with muscle invasive bladder cancer (MIBC). 3, 4 In some patients, even if the first diagnosis is non-muscle invasive bladder cancer (NMIBC), 10%-30% of patients progress to MIBC. 4, 5 BC has become a disease that seriously affects human health. 6, 7 At present, its early diagnosis and treatment have made great progress, 8, 9 but its specific mechanism of occurrence and development is still unclear. In recent years, non-coding RNAs (ncRNAs) have become a research hotspot. NcRNAs can be divided into housekeeping ncRNAs and regulatory ncRNAs. Among them, regulatory ncRNAs can be mainly divided into microRNA (miRNA), long noncoding RNA (ln-cRNA) and circular RNA (circRNA). [10] [11] [12] [13] LncRNA is a general term for single-stranded nucleotide sequences exceeding 200 bp. 14 Although it does not have the function of encoding proteins, it can participate in gene regulation at the epigenetic level, transcription level and post-transcriptional level, [15] [16] [17] affect tumour occurrence, development, metastasis and malignant progression of drug resistance. [18] [19] [20] [21] [22] [23] Based on the current research on the mechanism of lncRNA, the competitive endogenous 'ceRNA' mechanism is the most common type and a widely recognized regulatory mechanism, that is, some | 967 LIU ncRNAs have binding sites with microRNAs. 24, 25 The cell acts as a miRNA sponge, thereby releasing the inhibition of miRNA on the target gene, thereby increasing the expression level of the target gene. [26] [27] [28] [29] For instances, elevated LINC00909 can promote tumour progression of ovarian cancer via regulating the miR-23b-3p/MRC2 axis. 30 Long noncoding RNA IL6-AS1 is upregulated in chronic obstructive pulmonary disease and is interrelated to interleukin 6 via sponging miR-149-5p and regulating early B-cell factor 1 expression 31 ; Long non-coding RNA (lncRNA) DLEU2 can drive epithelialmesenchymal transition (EMT) genes and glycolysis in endometrial cancer through modulating the miR-455/HK2 and EZH2/miR-181a pathway. 32 Exosomes are small extracellular vesicles (EVs) (30-100 nm in diameter). 33, 34 They are secretory vesicles containing cytoplasmic protein and RNA in a bilayer of phospholipids and exist in all eukaryotic and prokaryotic cells. [35] [36] [37] Through their role as transporters, exosomes form complex networks that connect tumour cells in the tumour microenvironment and play a crucial role in these networks. [38] [39] [40] Carrying substances through autocrine, paracrine, endocrine and other signalling pathways, exosomes transport specific proteins, DNA and RNA to recipient cells, thereby regulating the biological characteristics of the recipient cells. [41] [42] [43] [44] For example, exosomes can promote tumour development, inhibit tumour cell apoptosis and immune escape, stimulate tumour angiogenesis and transfer genetic material. [45] [46] [47] [48] [49] [50] Recently, it has been shown that the release of exosomes may act as a vital role in the chemotherapy resistance of cancer cells by mediating the transfer of drugs, nucleic acids and proteins. [51] [52] [53] In recent years, studies have shown that exosomal-lncRNAs also play an indispensable role in the occurrence and progression of many cellular processes. Besides, exosomal lncRNAs can regulate the tumour microenvironment by modulating the expression of various key signalling pathways and molecular and play important regulatory roles in cancer metastasis. Moreover, due to their specificity and sensitivity, exosomal lncRNAs can also be released into tumour microenvironments and act as potential tumour markers. Ni et al. show that breast cancer-derived exosomal lnc-SNHG16 can enhance the activation of the TGF-β1/SMAD5 pathway through the miR-16-5p/SMAD5 regulatory axis, thereby inducing the expression of CD73 in Vδ1 T cells and leading to malignant tumour progression. 54 Li et al. identify that the expression of Lnc-FMR1-AS1 is increased in the tissues of patients with oesophageal cancer and is related to the poor prognosis of patients. 55 Lnc-FMR1-AS1 can be packaged into exosomes and released into the tumour microenvironment, and maintain the dynamic interconversion state of tumour stem cells by activating TLR7-NFκB signalling and up-regulating c-Myc levels in recipient cells. Guo et al. found that we can detect the occurrence of gastric cancer (GC) and predict the later progression of GC by detecting the expression of circulating exosomes lncRNA-GC1. 56 Combining the detection of circulating exosomes lncRNA-GC1 with endoscopy can improve the early diagnosis rate of GC. Lin et al. reveal that the AUC values of lncUEGC1 in distinguishing EGC patients from healthy individuals and patients with precancerous chronic atrophic gastritis were 0.8760 and 0.8406, respectively, which were higher than the diagnostic accuracy of carcinoembryonic antigen and were a good marker for early diagnosis of GC. 57 In this review, we focused on the latest evidence of major exosomal lncRNAs related to BC, and discussed the latent biological role of exosomal lncRNAs in the development, treatment and clinical applications of BC. There are two main secretion mechanisms of exosomes: con- Transmembrane proteins (such as CD9, CD63, CDS1), apoptosislinked gene 2 interacting protein X (ALIX), heat shock proteins (such as HSP70, HSP90). 45,58-60 Exosomes carry many nucleic acid molecules, such as miRNA, ncRNA and mRNA. 47, 50, 58 In addition, it also carries cytokines and growth factor proteins similar to the source cells. 60, 61 The biological process of exosome biogenesis and release was showed in Figure 1 . The separation methods of exosomes have not yet been unified, including sucrose gradient centrifugation, differential ultracentrifugation, filtration centrifugation, immunoaffinity capture technology, chromatography technology, microfluidic chip technology and PEG polymer precipitation. [62] [63] [64] The appropriate combination of these technologies may be effective. Even better, there are more commercial kits based on the above principles. The gold standard method is differential ultracentrifugation. 65, 66 The exosomes obtained by the sucrose gradient centrifugation method have high purity, but the preliminary preparation is time-consuming, the extraction process is very time-consuming and the yield is low. Exosomes can be stored at 4°C for a short term (within 1-2 days) and stored at 80°C for a long term. The identification of exosomes relies on morphological observation and protein composition analysis. 53, 67, 68 Observe the morphology of exosomes under an electron microscope. It can be seen that they are cup-shaped or flat balloons. Nanoparticle tracking analysis (NTA) can also be used to measure their diameters; protein composition analysis usually uses Western blot to detect exosomes. The protein expression level of body enrichment, as usual, chooses to detect CD63 and CD81. Exosomes were first discovered to participate in antigen presentation and immune activation and suppression. 69 Table 1 ). Epithelial-mesenchymal transition is intimately interrelated to the development of tissues or organs during embryogenesis. Additionally, this phenomenon is significantly associated with tumour development 87 and is a trigger for invasion, migration and acquisition of stem cell-like phenotype in cells of diverse cancers, including BC. 88 Cell proliferation is a precision control process, which is vital for embryonic and postnatal development. 94 Under pathological conditions, abnormal cell proliferation is a central mechanism attributing to disease progressions. Abnormal cell proliferation includes both F I G U R E 2 Role and functions of deregulated exosomal lncRNAs in BC progression. Exosomal lncRNAs can participate in the progression of BC by regulating the EMT (A), cell proliferation (B), lymphangiogenesis (C) and chemoresistance (D). Long noncoding RNA, lncRNA; bladder cancer, BC; HOX transcript antisense RNA, HOTAIR; epithelial-to-mesenchyme transition, EMT; urothelial cancer-associated 1, UCA1; phosphatase and tensin homologue deleted on chromosome ten, PTEN; micro RNA, miRNA; lymph node metastasis-associated transcript 2, LNMAT2; heterogeneous nuclear ribonucleoprotein A2B1, hnRNPA2B1; prospero homeobox 1, PROX1; ATP binding cassette subfamily B member 1, ABCB1; brain cytoplasmic RNA 1, BCYRN1; integration site family member 5A, Wnt5a; Vascular endothelial growth factor receptor 3, VEGF3; cancer-associated fibroblasts, CAFs; human lymphatic endothelial cells, HLECs. Long noncoding RNA, lncRNA; bladder cancer, BC; orthodenticle homeobox 2 antisense 1, OTX2-AS1; metastasis-associated lung adenocarcinoma transcript 1, MALAT1; prostate cancer-associated transcript 1, PCAT1; SPRY4 intronic transcript 1, SPRY4-IT1; phosphatase and tensin homolog pseudogene 1, PTENP1; small nucleolar RNA host gene 16, SNHG16; H19 imprinted maternally expressed transcript, H19 abnormal cell division and abnormal cell differentiation. 95 Besides, cell proliferation is also a main characteristic of cancer cells and the base of metastasis. 96 Studies have shown that exosomal lncRNAs can regulate the cell proliferation of BC ( Figure 2B ). Zheng and colleagues showed that exosomal PTENP1 was a novel biomarker that could be applied for clinical detection of BC. 97 Exosomes secreted by normal cells could transfer PTENP1 to BC cells and suppress cell growth and metastasis. The results indicated that exosomal PTENP1 might participate in the communication between normal cells and BC cells in the process of BC carcinogenesis. In addition, exosome-mediated could transfer LINC01133 inhibits the progression of BC by regulating the Wnt signalling pathway. 98 Tumour-induced lymphangiogenesis plays an essential role in promoting tumour growth and metastasis. 99 Tumour-associated lymphatic vessel density is closely correlated with sentinel lymph node metastasis, distant metastasis and patient survival. 100 In addition, lymph endothelial cells can interact with various immune cells to modulate immune cell activity. 101 Chemoresistance can be divided into primary drug resistance and multiple drug resistance (MDR). The former refers to cancer cells that are resistant to induced drugs, whereas the latter refers to cancer cells that develop resistance to induced drugs or other chemotherapeutic agents. 104 The establishment of chemoresistance in cancer cells involves various mechanisms, including downregulation of apoptosis, increased DNA repair, altered drug targets and overexpression of MDR proteins. 105 Studies have shown that exosomal lncRNAs can regulate the chemoresistance of BC ( Figure 2D ). Luo et al. proved that the CAFderived exosome LINC00355 could promote the resistance of BC cells to cisplatin by regulating the miR-34b-5p/ABCB1 axis. 107 Previous studies have shown that exosomal lncRNAs play a crucial role in the early diagnosis and prognostic evaluation of tumours. [108] [109] [110] [111] We summarized the diagnostic and prognostic value of exosomal-lncRNAs in BC (Table 2) . No matter how hard the current multidisciplinary treatment is, the high recurrence rate of BC is still the biggest obstacle for treatment. [116] [117] [118] The At present, studies have found that exosomal lncRNA has an important biological role in BC, but more research is still needed to explore the clinical translational value of exosomal lncRNAs in BC. Many studies have confirmed that exosomal lncRNAs can promote the malignant progression of tumours by promoting angiogenesis. [119] [120] [121] In addition, exosomal lncRNA can also mediate immunosuppressive microenvironments, 122,123 regulate cell radioresistance 124 and mediate metabolic reprogramming, 125 Due to its very aggressive nature, BC has the lower survival rate of urology cancers. [126] [127] [128] This extremely high mortality rate is primarily the result of its early asymptomatic development, so it is diagnosed as late. 129, 130 Therefore, there is an urgent need for new diagnostic tools and new treatment strategies. In recent years, the potential role of lncRNAs as biomarkers, therapeutic targets and therapeutics in cancer research have attracted increasing interest. However, the pathophysiological function of lncRNAs still remains unknown, and whether they are the cause or consequence of cancer remains to be determined. Additionally, the same lncRNA can play completely distinct roles in various cancer environments, which makes the characterization of lncRNA particularly difficult. Although most studies are still in the preclinical stage, the diagnostic and prognostic applications of lncRNA related to exosomes are very promising for BC treatment. New advances in lncRNAs-related studies in specific fields, such as bioinformatics, pharmacokinetics, and improved nanotechnology to deliver lncRNAs-containing exosomes to the tumour microenvironment, will lay the foundation for future clinical applications. Understanding the function and role of lncRNAs is essential for their effective use as biomarkers, precision medicine or therapeutic targets. We thank the generous support by Liaoning Cancer Hospital & Institute (Shenyang). The authors declare that there are no conflicts of interest. Qiang Liu: Original draft preparation, allocation, revision, supplement and edition. The data in the current study are available from the corresponding authors on reasonable request. https://orcid.org/0000-0001-6751-7096 Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines Clinical therapies and nano drug delivery systems for urinary bladder cancer Defining cisplatin eligibility in patients with muscle-invasive bladder cancer Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes The multifaceted immune regulation of bladder cancer The roles of t cells in bladder pathologies The biology and rationale of targeting nectin-4 in urothelial carcinoma Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation RNA structure probing uncovers RNA structure-dependent biological functions Non-coding RNAs regulation of macrophage polarization in cancer The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives Long noncoding RNAs in human stemness and differentiation Long noncoding RNAs: Potential therapeutic targets in cardiocerebrovascular diseases Molecular landscape of long noncoding RNAs in brain disorders Mechanisms of long noncoding RNA nuclear retention Long noncoding RNA loss in immune suppression in cancer Noncoding RNAs versus protein biomarkers in cardiovascular Disease The role of long noncoding RNAs in hepatocellular carcinoma Exosomal noncoding RNAs in Glioma: Biological functions and potential clinical applications Long non-coding RNAs regulate drug resistance in cancer Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application Long Noncoding RNAs and repetitive elements: junk or intimate evolutionary partners? The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management Long non-coding RNAs as new regulators of cardiac electrophysiology and arrhythmias: Molecular mechanisms, therapeutic implications and challenges Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia Elevated LINC00909 promotes tumor progression of ovarian cancer via regulating the miR-23b-3p/MRC2 axis Long noncoding RNA IL6-AS1 is highly expressed in chronic obstructive pulmonary disease and is associated with interleukin 6 by targeting miR-149-5p and early Bcell factor 1 Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/ miR-181a pathway The Yin and Yang of exosome isolation methods: Conventional practice, microfluidics, and commercial kits Artificial exosomes for translational nanomedicine DC-derived exosomes for cancer immunotherapy. Cancers (Basel) Extracellular vesicles as delivery systems at nano-/micro-scale Advances in microfluidic extracellular vesicle analysis for cancer diagnostics Central nervous system cell-derived exosomes in neurodegenerative diseases Role of exosomal mi-croRNAs and their crosstalk with oxidative stress in the pathogenesis of osteoporosis Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications Exosomal non-coding RNAs in hepatobiliary cancer: A rising star Extracellular vesicles as mediators of cancer disease and as nanosystems in theranostic applications Extracellular vesicles in the treatment of neurological disorders Emerging potential of exosomes on adipogenic differentiation of mesenchymal stem cells Advances, development and potential therapeutic strategies in diabetic nephropathy Extracellular vesicle nanoarchitectonics for novel drug delivery applications Exosomal microRNA in pancreatic cancer diagnosis, prognosis, and treatment: from bench to bedside. Cancers (Basel) Extracellular vesicles as an advanced delivery biomaterial for precision cancer immunotherapy Camouflage strategies for therapeutic exosomes evasion from phagocytosis Emerging roles of exosomal miRNAs in diabetes mellitus Extracellular vesicles in immune system regulation and Type 1 diabetes: Cell-to-cell communication mediators, disease biomarkers, and promising therapeutic tools Aspects of the tumor microenvironment involved in immune resistance and drug resistance Recent progress in detection and profiling of cancer cell-derived exosomes Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+gammadelta1 Treg cells Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/ NFkappaB/c-Myc signaling in female esophageal carcinoma Circulating exosomal gastric cancerassociated long noncoding RNA1 as a biomarker for early detection and monitoring progression of gastric cancer: A multiphase study Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer Emerging exosomes and exosomal MiRNAs in spinal cord injury The emerging role of exosomes in the treatment of human disorders with a special focus on mesenchymal stem cellsderived exosomes Exosomes as drug delivery vehicles and biomarkers for neurological and auditory systems Co-isolation of cytokines and exosomes: implications for immunomodulation studies Rapid separation of blood plasma exosomes from low-density lipoproteins via a hydrophobic interaction chromatography method on a polyester capillary-channeled polymer fiber phase Analysis of the regenerative capacity of human serum exosomes after a simple multistep separation from lipoproteins Comparison of an optimized ultracentrifugation method versus size-exclusion chromatography for isolation of exosomes from human serum Characterization of urinary exosomes purified with size exclusion chromatography and ultracentrifugation Proteomics comparison of exosomes from serum and plasma between ultracentrifugation and polymer-based precipitation kit methods Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs) Isolation and characterization of exosomes for cancer research Exosomes and tumor-mediated immune suppression Placenta-derived exosomes as a modulator in maternal immune tolerance during pregnancy Regulation of antitumor immune responses by exosomes derived from tumor and immune cells The pivotal roles of exosomes derived from endogenous immune cells and exogenous stem cells in myocardial repair after acute myocardial infarction Exosomes as mediators of immune regulation and immunotherapy in cancer The biology of exosomes in breast cancer progression: Dissemination, immune evasion and metastatic colonization. Cancers (Basel) Immune cell-derived exosomes in the cancerimmunity cycle Exosomes: Versatile nano mediators of immune regulation The emerging roles of exosomes in anticancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment Gene-engineered exosomesthermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy Exosomes and cancer stem cells in cancer immunity: current reports and future directions. Vaccines (Basel) Power and promise of exosomes as clinical biomarkers and therapeutic vectors for liquid biopsy and cancer control Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2 Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vgamma9Vdelta2 T cells by targeting specificity protein 1 Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma The amoeboid state as part of the epithelial-to-mesenchymal transition programme Tumor immune microenvironment during epithelial-mesenchymal transition Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-beta family Epithelial to mesenchymal transition: A challenging playground for translational research. current models and focus on TWIST1 relevance and gastrointestinal cancers Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1 Exosome-derived LINC00960 and LINC02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder cancer cells Mitofusin-2: A new mediator of pathological cell proliferation Neuroendocrine carcinomas with atypical proliferation index and clinical behavior: A systematic review. Cancers (Basel) Role of mi-croRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer Exosome-transmitted long noncoding RNA PTENP1 suppresses bladder cancer progression Dynamic monitoring of serum liver function indexes in patients with COVID-19 Avery-Kiejda K The roles of non-coding RNAs in tumor-associated lymphangiogenesis. Cancers (Basel) Targeting lymphangiogenesis and lymph node metastasis in liver cancer Role of Extracellular Vesicles on Cancer Lymphangiogenesis and Lymph Node Metastasis Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer The Emerging Role of Exosomes in Cancer Chemoresistance Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches Extracellular Vesicle-Associated miRNAs and Chemoresistance: A Systematic Review Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers Serum exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma Plasma exosomal long noncoding RNA lnc-SLC2A12-10:1 as a novel diagnostic biomarker for gastric cancer Serum exosomal long noncoding RNA pcsk2-2:1 as a potential novel diagnostic biomarker for gastric cancer Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis A panel of urinary long non-coding RNAs differentiate bladder cancer from urocystitis An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer Intravesical MMC and MMC+Ara-C for non-muscle invasive bladder cancer: A randomized clinical trial Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer Tumor-derived exosomal non-coding RNAs: The emerging mechanisms and potential clinical applications in breast cancer Highly enriched exosomal lncRNA OIP5-AS1 regulates osteosarcoma tumor angiogenesis and autophagy through miR-153 and ATG5 Pancreatic cancer cells-derived exosomal long non-coding RNA CCAT1/microRNA-138-5p/HMGA1 axis promotes tumor angiogenesis Immunosuppressive effects of hypoxiainduced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways Glioblastoma-associated microglia reprogramming is mediated by functional transfer of extracellular miR-21 Expression profiles and potential functions of circular RNAs in extracellular vesicles isolated from radio-resistant glioma cells Adjuvant immune checkpoint inhibition in muscle-invasive bladder cancer: Is it ready for prime time? The green anti-cancer weapon. The role of natural compounds in bladder cancer treatment Grape seed proanthocyanidins inhibit migration and invasion of bladder cancer cells by reversing emt through suppression of TGF-beta signaling pathway Proteomic profiling of tissue exosomes indicates continuous release of malignant exosomes in urinary bladder cancer patients, even with pathologically undetectable tumour Epithelial-to-mesenchymal transition enhances cancer cell sensitivity to cytotoxic effects of cold atmospheric plasmas in breast and bladder cancer systems How to cite this article: Liu Q. The emerging roles of exosomal long non-coding RNAs in bladder cancer